Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer

Authors not listed

SCRI Development Innovations, LLC · 2001

Abstract

In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-04 MST

Cite this

APA
Anonymous. (2001). A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer. <em>SCRI Development Innovations, LLC</em>. https://clinicaltrials.gov/study/NCT00193323
Vancouver
Anonymous. A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer. SCRI Development Innovations, LLC. 2001.
BibTeX
@misc{anon2001ARando, title = {A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer}, author = {Anonymous}, journal = {SCRI Development Innovations, LLC}, year = {2001}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings